Cannabidiol--recent advances.
The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity.
Mechoulam
Raphael
R
Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty, Jerusalem 91120, Israel. mechou@cc.huji.ac.il
Peters
Maximilian
M
Murillo-Rodriguez
Eric
E
Hanus
Lumír O
LO
D000818:Animals; D000975:Antioxidants / Q000138:chemical synthesis / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy; D002185:Cannabidiol / Q000819:agonists / Q000138:chemical synthesis / Q000627:therapeutic use*; D063387:Cannabinoid Receptor Antagonists; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects; D011957:Receptors, Opioid / Q000187:drug effects
D000975:Antioxidants; D063387:Cannabinoid Receptor Antagonists; D018696:Neuroprotective Agents; D011957:Receptors, Opioid; D044282:Receptor, Serotonin, 5-HT1A; D002185:Cannabidiol